New acne cream shows promise in small safety trial
NCT ID NCT06671834
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 28 times
Summary
Pfizer completed a Phase 1 study testing a new topical drug called PF-07905428 for acne. The study included 52 healthy volunteers and people with moderate to severe acne, who applied the drug daily for 14 or 28 days. The main goal was to check safety and side effects, not to see if it works. This early research helps decide if larger studies should go forward.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACNE VULGARIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Innovaderm Research Inc.
Montreal, Quebec, H2X 2V1, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PF-07905428 (topical solution)
What this could lead to
If it works, this could point toward a new topical treatment for moderate to severe acne.
What could go wrong
This is a very early Phase 1 study with only 52 participants, focused on safety. It is too small to prove effectiveness, and the drug may not work or may cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.